HomeACADEMIA
ACADEMIA

PI/II Study Suggests Efficacy of Eisai’s Anti-Fractalkine Antibody for RA
(Apr.25.2017)

Results of a PI/II clinical study of Eisai’s anti-fractalkine monoclonal antibody (development code: E6011) in Japanese patients with rheumatoid arthritis (RA) have suggested its clinical efficacy and novel pharmacotherapies that target fractalkine could provide new treatment options for RA ...
(LOG IN FOR FULL STORY)

News Calendar